Anzeige
Mehr »
Mittwoch, 09.07.2025 - Börsentäglich über 12.000 News
Schwergewicht aus London investiert Millionen in australisches Goldprojekt - was Anleger jetzt wissen müssen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
320 Leser
Artikel bewerten:
(2)

4Bio Capital: 4BIO Capital co-leads Actithera's oversubscribed $75.5 million Series A financing

4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention

Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures, and Sofinnova Partners, with syndicate including Bioqube Ventures, Surveyor Capital (a Citadel company) and others

Proceeds will support clinical development of Actithera's fibroblast activation protein (FAP)-targeting candidate and pipeline expansion

London, United Kingdom, 9 July 2025 - 4BIO Capital ("4BIO" or "the Group"), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that it has co-led a $75.5 million Series A Financing round of Actithera (the "Company").

Radiopharmaceutical therapy (or radioligand therapy, RLT) is a targeted form of radiotherapy that can treat cancers resistant to other therapies and represents a $7.5 billion market projected to grow to $14.4 billion by 20341. RLTs with the appropriate pharmacokinetic profile can achieve efficacy with minimal toxicity; however, attaining the ideal pharmacokinetic characteristics is not trivial. 4BIO's investment in Actithera highlights the clear need for a more systematic approach to optimizing RLT vectors and exemplifies the Group's strategy of identifying critical technology gaps, backing innovative solutions, and supporting them in high-growth markets.

4BIO co-led the oversubscribed round alongside founding investor M Ventures, Hadean Ventures, and Sofinnova Partners with additional participation from Bioqube Ventures, Innovestor's Life Science Fund, Investinor, Surveyor Capital (a Citadel company), and the second founding investor, Arkin Bio Ventures II.

Therese Liechtenstein, incoming Board Member and Investment Director at 4BIO Capital, said: "At 4BIO we invest in companies solving technical unmet needs to enable next-generation therapeutics. We are honoured to support Actithera, whose pipeline of molecules addresses key challenges in the nascent radioligand therapies space; a large therapeutic window through high tumour retention and low systemic exposure, applied to a lead programme that has significant pan-tumour therapeutic potential."

Dr Andreas Goutopoulous, Founder and CEO of Actithera, added: "We are grateful for 4BIO Capital's support in this oversubscribed Series A, which is a strong validation of our approach. We set out to bring structure-based and kinetics-driven thinking from small molecule drug design into the world of radiopharmaceuticals. We engineer our radioconjugates for extended retention within tumours, making them ideally suited for longer-lived radionuclides and ultimately delivering more convenient dosing schedules and enhanced efficacy and safety for patients."

As part of the Series A financing, Therese Liechtenstein, Investment Director at 4BIO Capital will join the Actithera Board of Directors.

The financing will support the advancement of Actithera's lead FAP asset into clinical development in multiple indications, while also enabling the continued development of its proprietary RLT discovery platform and preclinical pipeline.

The Company's discovery platform combines rational drug design with radiochemistry to create novel small molecule radioligands that overcome current limitations in radiopharmaceutical development. Its three-pillar platform includes first-in-class covalent targeting strategies, designed to optimize tumour residence time, while ensuring rapid systemic clearance - improving precision, safety, and efficacy. Two additional proprietary approaches further support compound differentiation and improve tumour residence time and selectivity. This platform was validated through Actithera's work on FAP, a high-value theranostic target known for being difficult to drug with molecules that maintain prolonged tumour residency. These efforts have resulted in a FAP-directed RLT development candidate with best-in-class potential due to its optimal pharmacokinetic profile and tumour specificity.

Dr Andreas Goutopoulos, founder and CEO, brings over 25 years of pharmaceutical and biotech industry experience, including a track record of more than a dozen development candidates. His background includes over a decade of discovery leadership at EMD Serono, where he led medicinal chemistry. In his role as Entrepreneur-in-Residence (EIR) at M Ventures, he led the scientific efforts of and supported a number of oncology small molecule biotechs. At Actithera, he is pioneering a chemistry-driven, precision approach to RLTs by integrating novel covalent-targeting chemistries, rational drug design principles and an isotope-agnostic philosophy.

- End -

Contacts

4BIO Capital+44 (0) 203 427 5500
info@4biocapital.com (mailto:info@4biocapital.com)
ICR Healthcare
Amber Fennell, Jonathan Edwards, Kris Lam
+44 (0)20 3709 5700
4biocapital@icrhealthcare.com



About 4BIO Capital
4BIO Capitaland Twitter @4biocapitaland visit www.4biocapital.com.

About Actithera
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapiesand on LinkedIn.


1 https://www.precedenceresearch.com/radiopharmaceuticals-market


© 2025 GlobeNewswire (Europe)
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.